BRIEF-Sophiris Bio Announces Complete Enrollment In Phase 2B Topsalysin Study
December 11, 2017 at 08:39 AM EST
* SOPHIRIS BIO ANNOUNCES COMPLETE ENROLLMENT IN PHASE 2B TOPSALYSIN STUDY OF LOCALIZED PROSTATE CANCER Source text for Eikon: Further company coverage: